What are drug courts? Do they work? Why are they so popular? Should countries be expanding them or rolling them back? These are some of the questions this volume attempts to answer. Simultaneously popular and problematic, loved and loathed, drug courts have proven an enduring topic for discussion in international drug policy debates. Starting in Miami in the 1980s and being exported enthusiastically across the world, we now have a range of international case studies to re-examine their effectiveness. Whereas traditional debates tended towards binaries like “do they work?”, this volume attempts to unpick their export and implementation, contextualising their efficacy. Instead of a simple yes or no answer, the book provides key insights into the operation of drug courts in various parts of the world. The case studies range from a relatively successful small-scale model in Australia, to the large and unwieldy business of drug courts in the US, to their failed scale-up in Brazil and the small and institutionally adrift models that have been tried in England, Scotland, Wales and Ireland. The book concludes that although drug courts can be made to work in very specific niche contexts, the singular focus on them as being close to a “silver bullet” obscures the real issues that societies must address, including (but not limited to) a more comprehensive and full-spectrum focus on diverting drug-involved individuals away from the criminal justice system.
About the author
Alexander Soderholm is the Policy Coordinator of the International Drug Policy Unit at the London School of Economics and Political Science (LSE), and the Managing Editor of the Journal of Illicit Economies and Development (LSE Press). He holds an MSc in International Development and Humanitarian Emergencies and is currently a Ph D Candidate in the LSE Department of Social Policy, studying drug policy and drug markets in the Islamic Republic of Iran. He has worked in a number of international contexts on issues related to drugs and development, including the United Nations Office on Drugs and Crime in Tehran. His research focuses on the intersection between drug markets and development outcomes, specifically on questions related to harm reduction and health, livelihoods and security.